Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 8, 2021 (HealthDay News) — mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines appear to be immunogenic in patients receiving immunosuppressive medications for the management of chronic inflammatory disease (CID), according to a study published online Aug. 31 in the Annals of Internal Medicine<\/em>.<\/p>\n Parakkal Deepak, M.B.B.S., from the Washington University School of Medicine in St. Louis, and colleagues determined the immunogenicity of mRNA-based SARS-CoV-2 vaccines in a volunteer sample of adults with confirmed CID who were eligible for early COVID-19 vaccination and immunocompetent participants recruited among hospital employees. Antibody responses were assessed following the two-dose vaccination series.<\/p>\n The researchers found that 88.7 percent of 133 participants with CID and all 53 immunocompetent participants developed antibodies in response to mRNA-based SARS-CoV-2 vaccination; numerically lower titers of anti-S IgG developed in some with CID. After vaccination, anti-S IgG antibody titers were lower in those with CID receiving versus those not receiving glucocorticoids; the geometric mean of anti-S IgG antibodies was 357 and 2,190 for those receiving and not receiving prednisone, respectively. Those receiving B-cell depletion therapy also had lower anti-S IgG antibody titers.<\/p>\n “Most patients with CID receiving immunosuppressive treatment were able to mount antibody responses, which provides justification for current recommendations for this population to be vaccinated,” the authors write.<\/p>\n One author disclosed financial ties to Pfizer.<\/p>\n